Aktis Oncology (NASDAQ:AKTS) Given Consensus Rating of “Moderate Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of analysts recently issued reports on the stock. William Blair assumed coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective for the company. Weiss Ratings started coverage on shares of Aktis Oncology in a research report on Tuesday, May 12th. They set a “sell (d)” rating for the company. TD Cowen started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating for the company. Finally, Leerink Partners started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company.

Aktis Oncology Stock Performance

AKTS opened at $20.34 on Friday. The firm’s 50-day moving average price is $18.67. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. Equities research analysts predict that Aktis Oncology will post -1.56 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.